Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of SAR444336 in Participants With Microscopic Colitis in Clinical Remission With Budesonide

NCT07156175 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07156175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07156175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of SAR444336 in Participants With Microscopic Colitis in Clinical Remission With Budesonide
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
October 14, 2025
Completion date
May 6, 2027
Enrollment
54 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

microscopic colitis